Biocon, Gland Pharma, Mphasis and Bandhan Bank may move out, says note by Nuvama Alternative & Quantitative Research
Meanwhile, the market's attention in the next few weeks will shift to the outcome of the Gujarat assembly election and the monetary policy action of the Reserve Bank of India (RBI)
LIC is aiming to increase its share of premium or participating policies to 15% in two years from about 9% presently, Kumar said
Global stock markets jumped on Thursday after minutes of the US Federal Reserve's November policy meeting hinted at a possible moderation in the pace of interest rate hikes
Says India's 'superior' earnings growth appears to be priced in, sees 'modest' contraction in P/E multiples going ahead; stay overweight on banks, insurers, and investment cyclicals
Limit exposure to this volatile category to 10-15% of equity portfolio, enter with 7-10-year horizon
Key benchmark indices are now within a striking distance of touching all-time highs after Friday's rally. Let's delve into the factors that can lead the benchmarks to new summits in the near term
Currently, the entity getting merged is removed from the index and later the weightage of the merged entity is increased
The adhesive maker's inclusion to be ad hoc; analysts divided over treatment around HDFC's removal
The plain-vanilla SIP, however, is simple and doesn't require a lump sum
The fall in the Indian market is far subdued, compared to many global peers that have slipped into bear-market territory
BSE has proposed that a stock must have a derivative contract to be eligible for inclusion in the flagship 30-share Sensex index
Equity valuations in India are among the highest globally on expectations of faster earnings growth
The 200-DMA is generally a good indicator of a long-term trend
US markets surge after worst September in two decades
With the rupee weakening against the US dollar, a more hawkish pivot by RBI is expected
Market players say issues have bunched up on account of companies rushing to hit the market before expiration of the result filing deadline
Financials and pharma stocks led the advance amid positive flows from foreign portfolio investors
The Nifty Pharma index finished at 12,750, up 3.1 per cent - most since May 20 and third biggest single-day gain of the year
'Defying global trends, Nifty 50 has outperformed most peers year-to-date and is trading at 19.2 times, 21% above its long-term average, taking the earnings yield-bond yield gap below 2%'